Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Slides:



Advertisements
Similar presentations
Medical Management for BPH: The Role of Combination Therapy
Advertisements

Pascal Rischmann  European Urology Supplements 
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum  John M. Fitzpatrick, Marc.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Advances in the Treatment of Metastatic Prostate Cancer
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Bladder Cancer: A Major Public Health Issue
Back to the Future: Introduction and Conclusions
Volume 71, Issue 1, Pages 1-3 (January 2017)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Volume 64, Issue 6, Pages (December 2013)
Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways  Kurt Miller, Arnulf.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Richard C. Harkaway  European Urology Supplements 
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 5, Pages (November 2006)
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Optimising Hormone Therapy in Advanced Disease
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
The Importance of Testosterone Control in Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
The Hallmarks of BPH Progression and Risk Factors
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer 2008: Challenges in Diagnosis and Management
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Bob Djavan  European Urology Supplements 
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
Highlighting Unmet Needs: Real Patients, Difficult Choices
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 53, Issue 6, Pages (June 2008)
Management of Prostate Cancer: Global Strategies
Beyond Skeletal-Related Events
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Manfred Wirth, Peter Iversen, David McLeod, William See 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Hormone Therapy: Improving Therapy Decisions and Monitoring
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Diagnosis and Management of Cryptorchidism
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Jan Roigas  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Introduction European Urology Supplements
Presentation transcript:

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders Per-Anders Abrahamsson  European Urology Supplements  Volume 8, Issue 11, Pages 821-822 (November 2009) DOI: 10.1016/j.eursup.2009.08.003 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Progression of prostate cancer and bone health. ADT = androgen-deprivation therapy; HRPC = hormone-resistant prostate cancer; PSA = prostate-specific antigen; SRE = skeletal-related event. European Urology Supplements 2009 8, 821-822DOI: (10.1016/j.eursup.2009.08.003) Copyright © 2009 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.